Katharina Eva Maria Kopp

Dr. Katharina Eva Maria Kopp

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1995 in Experimental and Applied Acarology
Verified
Journal Article
Closed access
PDF file
Katharina Eva Maria KoppKatharina Eva Maria Kopp
Katharina Eva Maria Kopp
RGR. Gothe
R. Gothe

10 July 2025 in Microbial Genomics
Verified
Journal Article
Open access
YCYasemin Coskun
Yasemin Coskun
SYSüleyman Yalçın
Süleyman Yalçın
EDEge Dedeoğlu
Ege Dedeoğlu
GÜGültekin Ünal
Gültekin Ünal
Katharina Eva Maria KoppKatharina Eva Maria Kopp
Katharina Eva Maria Kopp
SKSedat Kaygusuz
Sedat Kaygusuz
During the COVID-19 pandemic, next-generation sequencing (NGS) has been instrumental for public health laboratories in tracking severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations and informing responses. Illumina systems and Oxford Nanopore Technologies (ONT) have been primary tools for NGS, each presenting unique advantages. The hybrid assembly (HA) approach, integrating short- and long-read sequencing methods, has been developed to improve genome accuracy by utilizing the combined advantages of both techniques. While HA has been used to enhance SARS-CoV-2 genome quality, its optimal applications for SARS-CoV-2 sequencing and surveillance have not been systematically studied. This study seeks to address this gap by evaluating the conditions under which HA improves SARS-CoV-2 genomic surveillance, analysing 192 samples using eight bioinformatics methods across both platforms. HA was evaluated against single-technology approaches for its genome assembly and mutation detection performance. While HA did not outperform single-technology methods in detecting unique mutations, it produced marginally more complete genomes than Illumina-based methods. Importantly, mutations identified by HA were consistently detected across all eight methodologies, demonstrating its reliability in mutation detection. Moreover, our research underlines the critical need for in-house validation of methods and exposes the limitations inherent in proprietary pipelines. Our findings suggest that an HA approach could be used as a quality control tool in genomic surveillance, particularly for improving low-quality ONT sequencing data by integrating high-quality Illumina sequencing data. However, implementing HA demands the presence of both sequencing platforms and additional resources, such as hands-on time, expensive sequencing reagents and bioinformatics know-how. A decision-tree analysis identified the percentage of trimmed ONT reads relative to total reads as crucial for HA success, emphasizing the significance of high-quality ONT reads. This comprehensive approach provides public health laboratories insights to refine genomic surveillance strategies for SARS-CoV-2, potentially influencing future research and response efforts.

1 March 1995 in Experimental and Applied Acarology
Verified
Journal Article
Closed access
PDF file
Katharina Eva Maria KoppKatharina Eva Maria Kopp
Katharina Eva Maria Kopp
RGR. Gothe
R. Gothe

16 March 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
Katharina Eva Maria KoppKatharina Eva Maria Kopp
Katharina Eva Maria Kopp
ISIna Smith
Ina Smith
RKReuben Klein
Reuben Klein
STShawn Todd
Shawn Todd
GMGlenn A. Marsh
Glenn A. Marsh
AWAlister C. Ward
Alister C. Ward
Five species within the genera Ebolavirus and Marburgvirus of the family Filoviridae are known to cause severe hemorrhagic fever with high mortality rates in humans and non-human primates. Recent large outbreaks of Ebola virus disease in West Africa (2014 - 2016) and the Democratic Republic of the Congo (2018 - ongoing) have demonstrated the epidemic potential with devastating public health consequences. Several known and novel filovirus species have been found in bats in recent years. However, the role of each virus species in the disease ecology of human disease is still unclear. In particular, the transmission mechanism from potential animal hosts to humans is not known. Therefore, a simple, flexible, cost-effective screening tool for detecting the presence of any (putative) member of the filovirus family in animal samples is needed. In this study, a one-step conventional pan-filovirus RT-PCR assay was developed. The designed universal consensus primers of this screening test target two highly conserved regions of the nucleoprotein (NP) of all currently known filoviruses. The assay was capable of specific amplification of viral RNA of all six primate-pathogenic (human and non-human) filovirus species and resulted in 317 bp long RT-PCR products. This amplicon length renders the assay suitable for flexible application as conventional reverse transcription polymerase chain reaction (RT-PCR) as well as for future use as rapid real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR).

5 June 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Katharina Eva Maria KoppKatharina Eva Maria Kopp
Katharina Eva Maria Kopp
Whole-genome sequencing (WGS) is central to outbreak response for high-consequence ribonucleic acid (RNA) viruses, but useful genomes depend on workflow design, sample quality, biosafety, diagnostic breadth, infrastructure, and bioinformatics as much as sequencing platform. The 2026 Bundibugyo virus disease outbreak in the Democratic Republic of the Congo and Uganda provides a case example. Bundibugyo virus (BDBV) was already known from the 2007–2008 Uganda and 2012 Democratic Republic of the Congo outbreaks, but sparse historical genome sampling, Ebola virus-centered diagnostic assumptions, non-specific febrile and viral hemorrhagic fever presentations, and difficult field conditions created a need for broad differential diagnosis, rapid species assignment, and representative genome generation. This Review compares outbreak WGS strategies by the degree of prior viral sequence knowledge required, distinguishing direct RNA sequencing, random-primed complementary DNA (cDNA) sequencing, sequence-independent amplified cDNA sequencing, background-depleted or particle-enriched cDNA sequencing, probe-based hybrid capture, tiled amplicon sequencing, portable field sequencing, culture-derived sequencing, and associated bioinformatics workflows. For BDBV-like outbreaks, the most defensible strategy is staged and adaptive: broad viral hemorrhagic fever and febrile-illness differential testing at recognition; Filoviridae-wide testing when filovirus disease remains plausible; divergence-tolerant first-genome recovery; quantification-cycle-informed sequencing prioritization without BDBV-only diagnostic narrowing; validated amplicon scale-up; and representative sequencing across locations and time.

15 July 2026 in Viruses
Verified
Journal Article
Open access
PDF file
Katharina Eva Maria KoppKatharina Eva Maria Kopp
Katharina Eva Maria Kopp
Bundibugyo virus disease, caused by Bundibugyo virus (Orthoebolavirus bundibugyoense), is a severe human Ebola disease with substantial mortality, unresolved reservoir ecology, limited diagnostic implementation, and no licensed vaccines or therapeutics specifically approved for this Orthoebolavirus species. The May 2026 public health emergency in the Democratic Republic of the Congo and Uganda renewed the need for a focused synthesis of Bundibugyo virus-specific diagnostics and medical countermeasures. This review synthesizes the peer-reviewed literature, preprints, and official public-health documents on diagnostics, antivirals, therapeutics, vaccines, and post-exposure prophylaxis. Comparative evidence from the Ebola virus, Sudan virus, Marburg virus, and pan-filovirus platforms is included only where it clarifies Bundibugyo virus-specific evidence, exposes unsupported extrapolation, or defines preparedness gaps. The 2007–2008 outbreak showed that assays optimized for known filoviruses can miss divergent ebolaviruses; the 2026 outbreak underscored the importance of diagnostic breadth, sequencing-based confirmation, decentralized laboratory capacity, and regional coordination. Clinical and immunological data indicate that Bundibugyo virus cannot be reduced to an Ebola virus-like model. Countermeasure evidence remains largely preclinical: recombinant vesicular stomatitis virus vaccines expressing Bundibugyo virus glycoprotein provide the strongest direct animal protection data, whereas antiviral and antibody-based evidence varies widely and requires careful separation of direct Bundibugyo virus data from platform-based extrapolation.